CN115429788B - 一种治疗脱髓鞘疾病的药物及应用 - Google Patents
一种治疗脱髓鞘疾病的药物及应用 Download PDFInfo
- Publication number
- CN115429788B CN115429788B CN202211303009.0A CN202211303009A CN115429788B CN 115429788 B CN115429788 B CN 115429788B CN 202211303009 A CN202211303009 A CN 202211303009A CN 115429788 B CN115429788 B CN 115429788B
- Authority
- CN
- China
- Prior art keywords
- kaempferol
- mice
- eae
- eae mice
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000016192 Demyelinating disease Diseases 0.000 title claims abstract description 32
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 229940079593 drug Drugs 0.000 title description 3
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 claims abstract description 59
- 241000699670 Mus sp. Species 0.000 claims abstract description 44
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 claims abstract description 28
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 235000008777 kaempferol Nutrition 0.000 claims abstract description 28
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 claims abstract description 28
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000003210 demyelinating effect Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000009251 neurologic dysfunction Effects 0.000 claims description 2
- 208000015015 neurological dysfunction Diseases 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 12
- 206010012305 Demyelination Diseases 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000008595 infiltration Effects 0.000 abstract description 7
- 238000001764 infiltration Methods 0.000 abstract description 7
- 210000005036 nerve Anatomy 0.000 abstract description 5
- 230000002265 prevention Effects 0.000 abstract description 5
- 230000004064 dysfunction Effects 0.000 abstract description 3
- 208000003926 Myelitis Diseases 0.000 abstract description 2
- 239000013585 weight reducing agent Substances 0.000 abstract description 2
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000008096 xylene Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010033799 Paralysis Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002791 soaking Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 4
- 229910052808 lithium carbonate Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000004885 white matter Anatomy 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 229960002725 isoflurane Drugs 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000003007 myelin sheath Anatomy 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- -1 flavonoid compound Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010067601 Dysmyelination Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000029067 Neuromyelitis optica spectrum disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000012898 Olfaction disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 1
- 229960004419 dimethyl fumarate Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003517 fume Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 229950003873 triciribine Drugs 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗脱髓鞘疾病的药物,由山奈酚组成。本发明经实验证实,山奈酚对EAE小鼠有很好的预防和治疗效果,可以显著缓解EAE小鼠的神经功能障碍,减缓EAE小鼠体重下降的趋势,降低疾病神经功能评分,并延迟发病时间。山奈酚在40mg/kg/d给药浓度时能明显减轻EAE小鼠的脊髓炎性浸润,抑制EAE小鼠中枢神经***的髓鞘脱失。本发明为山奈酚开辟了新的用途,为临床治疗中枢神经***脱髓鞘疾病提供新的候选药物。
Description
技术领域
本发明涉及中医药研究开发利用领域,具体地说,是一种治疗脱髓鞘疾病的药物及应用。
背景技术
脱髓鞘疾病(Demyelinating Disease)是一种神经***疾病,是髓鞘形成障碍或遭到破坏,所导致的疾病的统称。脱髓鞘疾病可以分为中枢神经***脱髓鞘疾病(最多见,其中以多发性硬化、视神经脊髓炎谱系疾病为代表)、周围神经***脱髓鞘疾病,以及中枢和周围神经***联合脱髓鞘疾病。
多发性硬化(Multiple sclerosis,MS)是中枢神经***的自身免疫性脱髓鞘疾病。在全球范围内,约有200多万人罹患该病,主要临床表现是运动障碍,视力、味觉、嗅觉、认知和精神障碍,共济失调等,具有高致残率和高复发率的特点,严重影响患者的生活质量,给患者家庭和社会带来沉重的经济负担。MS发病机制尚不清楚,且当前没有彻底治愈该疾病的特效药物,临床上多采用格列吡啶、富马酸二甲酯、β干扰素和激素等药物缓解疾病的进展和复发,但是存在药物耐受和毒、副作用大等缺点。
中医药在治疗MS疾病方面具有资源丰富,疗效显著,毒、副作用小、价格低廉等独特优势,从中医药角度寻求有效治疗MS疾病的药物和疗法获得愈来愈多的国内外学者的关注。山奈酚(Kaempferol,Kae)是黄酮类化合物,广泛存在于多种蔬菜、水果以及中草药等植物中,最近研究发现山奈酚作为一种常见且安全的膳食补充剂,具有抗炎、抗癌、抗抑郁、抗惊厥和保护脑缺血损伤等作用。
为了寻求新的治疗中枢神经***脱髓鞘疾病的药物,本发明以山奈酚为研究对象,观察山奈酚对MS疾病的治疗效果,采用MS的经典动物模型--EAE小鼠进行实验研究,发现山奈酚对EAE脱髓鞘小鼠有很好的预防和治疗效果,显著改善其神经功能障碍,减轻中枢炎性浸润,抑制脱髓鞘。
目前尚未见山奈酚作为治疗中枢神经***脱髓鞘疾病的药物的相关研究和报道。
发明内容
本发明的目的是针对现有技术中的不足,提供一种治疗脱髓鞘疾病的药物。
本发明的另一目的是,提供一种上述药物的用途。
为实现上述第一个目的,本发明采取的技术方案是:
一种治疗脱髓鞘疾病的药物,所述的药物山奈酚是一种天然黄酮类化合物,其结构式(Ⅰ)所示。
优选地,所述药物为胶囊剂、片剂、粉剂、注射液或外用剂。
为实现上述第二个目的,本发明采取的技术方案是:
如上所述的药物在制备预防/治疗脱髓鞘疾病药物中的应用。
优选地,所述的脱髓鞘疾病为中枢神经***脱髓鞘疾病,采用的脱髓鞘疾病动物模型是EAE。
优选地,所述的中枢神经***脱髓鞘疾病为多发性硬化疾病。
优选地,所述山奈酚在制备改善EAE小鼠的神经功能障碍、抑制中枢神经***炎性浸润和髓鞘脱失药物中的用途。
本发明优点在于:
1、山奈酚对EAE小鼠有很好的预防和治疗效果,可以显著缓解EAE小鼠的神经功能障碍,减缓EAE小鼠体重下降的趋势,降低疾病神经功能评分,并延迟了发病时间。山奈酚在40mg/kg/d给药浓度时能明显减轻EAE小鼠的脊髓炎性浸润,抑制EAE小鼠中枢神经***的髓鞘脱失。
2、本发明为山奈酚开辟了新的用途,为临床治疗中枢神经***脱髓鞘疾病提供新的候选药物。
附图说明
附图1是成功构建EAE小鼠模型;
附图2是实验各组小鼠的神经功能评分;
附图3是实验各组小鼠的体重变化;
附图4是实验各组小鼠的脊髓HE染色;
附图5是实验各组小鼠的脊髓LFB染色。
具体实施方式
下面结合具体实施方式,进一步阐述本发明。应理解,实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1山奈酚对EAE脱髓鞘小鼠的作用
1.实验材料
1.1动物
健康雌性C57BL/6小鼠24只,6周龄,体重18~20g,购于上海斯莱克实验动物有限公司,SPF级环境(恒温25±2℃,恒湿40%~50%)喂养。
1.2试剂
山奈酚、生理盐水、百日咳毒素、完全弗氏佐剂、结核分枝杆菌H37Ra、MOG35-55、4%多聚甲醛。
1.3仪器
电动组织匀浆器(上海净信实业发展有限公司)、漩涡振荡仪(海门其林贝尔仪器公司)、电子天平(上海舜宇恒平仪器公司)。
2.实验过程
2.1EAE模型乳化试剂的准备
MOG35-55溶于PBS缓冲液,配置终浓度为2mg/ml,在完全弗氏佐剂(CFA)中加入结核分枝杆菌H37Ra至终浓度4mg/ml,将MOG35-55溶液与CFA按1:1体积比进行乳化,采用电动组织匀浆器调至100W超声60分钟,冰上操作,超声1分钟,停止1分钟,防止温度过高影响试剂活性,待充分乳化后将乳化剂滴在水面,乳化剂聚集而不会分散,既为乳化成功。
2.2百日咳毒素(PTX)的配置
将0.2mg/mlPTX用PBS缓冲液稀释至300ng/ml。
2.3C57BL/6小鼠免疫方法
在免疫当日(Day0)异氟烷麻醉小鼠,于小鼠脊柱头颈部和后背分两点注射MOG35-55乳化剂各100μl。即MOG35-55200μg/只,腹腔注射PTX溶液200μl,即PTX 200ng/只,并观察小鼠麻醉后苏醒状态是否良好;在免疫后第2天(Day2)再次腹腔注射PTX 200ng/只。
2.4分组和给药方式
实验前将6周龄的小鼠称重,随机抽取小鼠,分配到各组,设为正常组8只,EAE组8只,山奈酚给药组8只,适应性喂养1周。正常组不进行干预,正常喂养;EAE组是自免疫当天开始用生理盐水灌胃0.2ml/只;山奈酚组是在免疫前7日起开始给药,每只小鼠按照40mg/kg/d的标准灌胃,直至实验结束。
3.一般情况观察
3.1体重检测
自免疫当日(Day0)起,每日对实验各组小鼠进行称量,并记录小鼠体重的变化,直至免疫后30天(Day30)。
3.2疾病神经功能评分
从免疫当日起对实验小鼠进行一般情况监测,记录神经功能评分,评分标准根据国际通用的5级评分进行评分:
①0分无异常表现;
②0.5分部分尾部瘫痪;
③1分尾部完全瘫痪;
④2分后肢轻度瘫痪或步态不稳;
⑤3分后肢完全瘫痪;
⑥3.5分双后肢完全瘫痪,前肢轻度瘫痪;
⑦4分四肢完全瘫痪;
⑧4.5分濒死状态;
⑨5分死亡。
4.结果
4.1EAE小鼠发病典型症状
通过前期预实验掌握了构建成熟稳定的EAE小鼠模型方法。EAE组小鼠发病起始于造模后第11天,发病高峰出现于造模后第17天,17天后病情逐渐进入缓解期,EAE小鼠最高临床症状评分为4分,在整个实验过程中未出现小鼠死亡,EAE小鼠的发病率为100%(图1)。
4.2山奈酚对EAE小鼠的神经功能评和分体重的影响
与EAE组相比,山奈酚组小鼠的发病起始及发病高峰时间均有所延迟,分别为第14天和第20天,临床症状评分显著降低,山奈酚对于缓解EAE小鼠的临床症状具有一定预防和治疗作用(图2)。在EAE模型诱导后,各组小鼠的体重均有所下降,免疫后第4天起体重逐渐缓慢上升;EAE组小鼠临近发病期体重开始出现显著下降,并且随病情加重而持续减轻,山奈酚干预显著减缓了EAE小鼠的体重下降趋势(图3)。
实施例2:山奈酚对EAE脱髓鞘小鼠中枢神经***的作用
1.材料和方法
1.1试剂
生理盐水、多聚甲醛、异氟烷、苏木精、伊红、LFB染色液、二甲苯、各种浓度梯度的乙醇、碳酸锂溶液、中性树胶。
1.2仪器
精密鼓风干燥箱(上海博迅医疗生物仪器公司)、倒置显微镜(日本奥林巴斯)、石蜡包埋机、石蜡切片机(德国Leica公司)、水浴锅(上海精宏实验设备公司)。
1.3动物取材:
在免疫后30天结束实验,异氟烷口鼻吸入进行麻醉,小鼠进行固定,打开小鼠胸腔,暴露出心脏,剪开心包膜,用穿刺针快速从左心室***,动脉夹固定针尖,灌注少量生理盐水,待右心房逐渐膨胀时,剪开右心耳排液,继续灌注生理盐水30毫升,直至肝脏变白,换4%多聚甲醛灌注,直至小鼠尾巴***,四肢强直,表明固定成功。停止灌注,剪开小鼠的枕顶部皮肤,剥离颅骨,完整取出大脑,剥离小鼠的脊柱(腰膨大部位),PBS清洗后,放入多聚甲醛中浸泡24h,准备包埋、切片,进行后续实验。
1.4HE染色方法:
①将石蜡切片置于烘箱中60℃烤1~2h;
②脱蜡:脱蜡二甲苯I、II各10分钟,提前准备好盖玻片;
③覆水:100%(I、II)、90%、80%、70%酒精各5分钟,自来水冲洗5分钟×3。
④苏木精染色5分钟,根据染色情况,可以适当增加或减少染色时间,流水冲洗。
⑤5%乙酸分化1分钟,流水冲洗,用吸管滴加乙酸,布满玻片上的组织即可,分化后颜色变浅成为蓝色。
⑥伊红染色1分钟,根据染色情况,可以适当增加或减少染色时间,流水冲洗。
⑦脱水:70%、80%、90%、100%乙醇各10秒,二甲苯1分钟,可以在通风橱自然晾干再封片,约5分钟左右。
⑧滴上中性树胶,封片,用吸管滴上一滴即可,尽量少滴,但压片后要将组织全部覆盖完,避免中间有气泡。
1.5LFB髓鞘染色方法:
①选好片子,放60℃烘箱2h,使石蜡融化。
②脱蜡至95%乙醇:二甲苯I 30分钟→二甲苯II 30分钟→二甲苯III 30分钟→无水乙醇I 2分钟→无水乙醇II 2分钟→95%乙醇2分钟;
③LFB染色:在0.1%LFB染色液中过夜室温孵育16h;
④洗片:第二天取出片子→95%乙醇稍浸洗→纯水中稍浸洗;
⑤分化:0.05%的碳酸锂溶液进行分化,10s左右,放入70%乙醇稍浸洗,显微镜下观察脑灰质和白质能清晰辨别,灰质接近于透明色,白质是蓝绿色,停止分化,纯水稍浸洗;
⑥脱水、透明:80%乙醇2分钟→90%乙醇2分钟→无水乙醇I 2分钟→无水乙醇II2分钟→二甲苯I 2分钟→二甲苯II 2分钟
⑦滴上中性树胶,封片。用吸管滴上一滴即可,尽量少滴,但压片后要将组织全部覆盖完,避免中间有气泡,晾干后倒置显微镜进行拍照。
2.结果
2.1山奈酚抑制EAE脱髓鞘小鼠的炎性浸润
HE染色显示,正常组小鼠的腰膨大部位细胞结构清晰,排列整齐,细胞间隙分明,无水肿、无炎性浸润、细胞坏死的等现象;EAE小鼠腰膨大部位损伤明显,细胞排列紊乱,炎性细胞大量浸润,核质界限不明,染色质固缩或聚集严重;与EAE组相比,山奈酚组小鼠的腰膨大损伤得到明显缓解,细胞排列整齐,细胞间隙分明,无炎性细胞浸润,染色质固缩或聚集严重等现象(图4)。
2.2山奈酚抑制EAE小鼠的髓鞘脱失
LFB染色显示髓鞘被染成蓝色(因说明书中图片呈现灰色,以此说明),正常小鼠的髓鞘组织结构完整,分布均匀,无髓鞘脱失;EAE小鼠脊髓可见大小不等的片状髓鞘脱失区域,白质中的空泡样脱髓鞘改变尤为明显;山奈酚给药组小鼠的髓鞘比较完整,质地均匀,髓鞘脱失程度明显得到抑制(图5)。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明方法的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (2)
1.山奈酚在制备预防/治疗中枢神经***脱髓鞘疾病药物中的用途,其特征在于,所述的中枢神经***脱髓鞘疾病为多发性硬化疾病。
2.根据权利要求1所述的用途,其特征在于,所述山奈酚还可用于制备改善EAE小鼠的神经功能障碍、抑制中枢神经***炎性浸润和髓鞘脱失药物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211303009.0A CN115429788B (zh) | 2022-10-24 | 2022-10-24 | 一种治疗脱髓鞘疾病的药物及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211303009.0A CN115429788B (zh) | 2022-10-24 | 2022-10-24 | 一种治疗脱髓鞘疾病的药物及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115429788A CN115429788A (zh) | 2022-12-06 |
CN115429788B true CN115429788B (zh) | 2023-11-21 |
Family
ID=84252608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211303009.0A Active CN115429788B (zh) | 2022-10-24 | 2022-10-24 | 一种治疗脱髓鞘疾病的药物及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115429788B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104306368A (zh) * | 2014-10-09 | 2015-01-28 | 中国人民解放军第二军医大学 | 山奈酚在制备抗hcv感染药物中的应用 |
KR20190063238A (ko) * | 2017-11-29 | 2019-06-07 | 재단법인 경기도경제과학진흥원 | 칠해목으로부터 분리한 화합물을 유효성분으로 함유하는 뇌신경세포 보호용 조성물 |
WO2022013874A1 (en) * | 2020-07-14 | 2022-01-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising cannabinoids, terpenes, and flavonoids for treating depression |
CN114007607A (zh) * | 2019-02-05 | 2022-02-01 | 加州大学评议会 | 用于治疗神经变性疾病的材料和方法 |
-
2022
- 2022-10-24 CN CN202211303009.0A patent/CN115429788B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104306368A (zh) * | 2014-10-09 | 2015-01-28 | 中国人民解放军第二军医大学 | 山奈酚在制备抗hcv感染药物中的应用 |
KR20190063238A (ko) * | 2017-11-29 | 2019-06-07 | 재단법인 경기도경제과학진흥원 | 칠해목으로부터 분리한 화합물을 유효성분으로 함유하는 뇌신경세포 보호용 조성물 |
CN114007607A (zh) * | 2019-02-05 | 2022-02-01 | 加州大学评议会 | 用于治疗神经变性疾病的材料和方法 |
WO2022013874A1 (en) * | 2020-07-14 | 2022-01-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising cannabinoids, terpenes, and flavonoids for treating depression |
Non-Patent Citations (3)
Title |
---|
Rahul ,等.Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol.CNS & Neurological Disorders - Drug Targets.2021,第20卷(第4期),第327页摘要. * |
山奈酚对脑缺血再灌注大鼠神经元超微结构及TLR4/NF-κB的影响;向丽;董志;李然然;曹光秀;刘洁;;中国医院药学杂志;第35卷(第10期);869-873 * |
淫羊藿黄酮对实验性自身免疫性脑脊髓炎大鼠模型病理特征的干预;尹琳琳;林丽莉;李林;;中国药学杂志;第46卷(第18期);1412-1416 * |
Also Published As
Publication number | Publication date |
---|---|
CN115429788A (zh) | 2022-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102058817B (zh) | 一种治疗肝病的藏药制剂 | |
CN104366510A (zh) | 茶叶茶氨酸保健食品组合物及其制备方法 | |
CN102028700B (zh) | 一种药物组合物及其制备方法 | |
JPH0368006B2 (zh) | ||
CN101856418B (zh) | 防治肾炎的药物制剂及其制备方法 | |
CN101647951B (zh) | 一种中药组合物及其制备方法和应用 | |
CN115429788B (zh) | 一种治疗脱髓鞘疾病的药物及应用 | |
CN112370496A (zh) | 枸杞叶有效成分在制备预防或治疗肝纤维化药物中的应用 | |
Hartman | Studies on the function and clinical use of cortin | |
CN103055176B (zh) | 一种治疗糖尿病的中药及其制备方法 | |
CN105663966A (zh) | 一种用于减肥瘦身、降脂的组合物 | |
CN102106993B (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN101822729A (zh) | 用于治疗缓慢性心律失常病态窦房结综合征的药物 | |
CN101574359A (zh) | 一种治疗心脑血管疾病的药物组合物 | |
CN117224526A (zh) | 毛蕊异黄酮在治疗脱髓鞘疾病中的应用 | |
CN104257755A (zh) | 一种具有治疗糖尿病作用的组合物及其制备方法和应用 | |
CN115779046B (zh) | 一种防治糖尿病的中药组合物、中药制剂与应用 | |
CN115624543B (zh) | 治疗偏头痛的药物、药物组合物、其制备方法和制药用途 | |
CN107737108A (zh) | 一种治疗心肌梗死后心室重塑的口服药物组合物 | |
CN116173096B (zh) | 一种治疗脑卒中的药物组合物及其制备方法和用途 | |
CN107998134A (zh) | 可博美在制备辅助治疗糖尿病足的药物制剂中的应用 | |
EP0719556A2 (en) | Agent for treating diabetic keratopathy | |
CN107349318B (zh) | 一种降血脂瓜蒌皮复方及其制备方法 | |
CN106492008B (zh) | 一种用于制备抗糖尿病肾病产品的中药组方及其制备方法和用途 | |
CN1857293A (zh) | 一种含有野黄芩苷和芍药苷的药用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |